2023 ANNUAL REPORT
The 2023 annual report outlines Alpha-1 Org Australia’s commitment to supporting for individuals suffering with Alpha-1.
A1AD is a common genetic (inherited) disorder associated with low levels of a natural protein known as Alpha-1 Antitrypsin (AAT). Low levels of AAT can cause a number of diseases.
You are likely to have a lot of questions following a diagnosis of Alpha-1 Antitrypsin Deficiency (A1AD). Select the questions in the attachment that best relate to you.
There is only one treatment available to protect the lungs of people with A1AD. The treatment is Alpha-1 proteinase inhibitor (also called Augmentation Therapy).
A position paper from Gaynor Heading PhD (Med), President of Alpha-1 Organisation Australia, focusing on preventing harm and saving lives for individuals with A1AD.